Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
24 juin 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
23 juin 2024 13h30 HE
|
Fractyl Health, Inc.
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Platform at ADA 2024.
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
22 juin 2024 08h00 HE
|
MannKind
INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED
SAb Biotherapeutics Rebrands as SAB BIO
20 juin 2024 07h20 HE
|
SAB Biotherapeutics, Inc.
New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE...
Talisman needle-free CGM demonstrates strong correlation to blood glucose in clinical studies and moves towards large volume manufacturing
17 juin 2024 02h00 HE
|
GlucoModicum
Talisman needle-free CGM demonstrates strong correlation to blood glucose in clinical studies and moves towards large volume manufacturing Data from Clinical Performance Study of Talisman shows...
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
13 juin 2024 06h38 HE
|
ADALVO LIMITED
Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
13 juin 2024 06h00 HE
|
Biosplice Therapeutics, Inc.
Biosplice enters into a pre-clinical collaboration with Novo Nordisk to develop inhibitors of DYRK for diabetes
GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
05 juin 2024 08h30 HE
|
GlucoTrack, Inc.
Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet...
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
05 juin 2024 06h45 HE
|
MannKind
INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION’S 84TH SCIENTIFIC SESSIONS
Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications
24 mai 2024 03h00 HE
|
Atrogi
STOCKHOLM, Sweden, May 24, 2024 (GLOBE NEWSWIRE) -- Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces a publication in the Journal of...